

08-30-01



CASE 3285 US



NEW APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Khanna et al.

TITLE: BICYCLIC ALPHA-V BETA-3 ANTAGONISTS

Commissioner of Patents and Trademarks Washington, D. C. 20231

Transmitted herewith for filing is the above-identified patent application which, in Sir: accordance with 37 CFR 1.51, comprises:

[X]	Abstract and Specification including 16 Claims (123 pages)
[]	Sequence listing
[]	Diskette (Sequence Listing)
[]	An Assignment of the application and a Declaration and Power of Attorney
[X]	An Assignment of the application and a Declaration and Power of Attorney to follow under separate cover
[]	Sheets of formal/informal drawings
[X]	Post Card
[]	Prior Art Statement (37 CFR 1.97)
[]	Preliminary Amendment
[X]	A triplicate copy of this transmittal paper is enclosed.
[X]	The present application claims priority under Title 35, United States Code, §119 of United States Provisional application Serial No. 60/228,693 filed August 29, 2000.

The Commissioner is hereby authorized and requested to charge any fees* in addition to the above as well as all future fees set forth in 37 CFR 1.16 and 1.17 which may be required during the entire pendency of this Application, and credit any overcharges to Deposit Account No. 19-1025. NOTE: THIS AUTHORIZATION DOES NOT INCLUDE FERS REQUIRED UNDER 37 CFR 1.18

Pharmacia Corporation Corporate Patent Department 800 N. Lindbergh Blvd. Mail Zone O4E St. Louis, MO 63167

Rachel A. Polster Agent for Applicants Registration No. 47,004 636-737-5761

* Calculated as follows:

Basic Fee Total Claims in Excess of 20 X \$18 (0 X \$18) Independent Claims in Excess of 3 X \$78 (0 X \$78) Surcharge for Multiple Dependent Claim(s) (\$270) FILING FEE

\$ 710.00 0.00 0

270.00 \$980.00